Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Luspatercept (Reblozyl) in Adults and Adolescents with Alpha (α)-thalassemia HbH Disease
2022-502328-35-00Phase 2Authorised
- Sponsor
- Celgene Corporation
- Start
- Jul 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised trial of luspatercept in alpha-thalassemia intermedia and anaemia (4 arms), sponsored by Celgene Corporation. Primary endpoints: Adult TD cohort – primary efficacy endpoint, Adult NTD cohort – primary efficacy endpoint and 3 more. Planned start Jul 2023; status: authorised.
02
Drugs
luspatercept
03
Conditions
alpha-thalassemia intermediaanaemia
Beyond the preview
Go deeper on 2022-502328-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502328-35-00.